

## Procedure to vote at the Combined Shareholders Meeting of May 24, 2023

Editorial by the CEO  
of GENFIT



Dear Shareholders,

**The next GENFIT Combined Shareholders Meeting will take place on May 24, 2023 at 10.00am** at the Lille Faculty of Pharmacy situated at 3, rue du Professeur Laguesse, Lille, and we invite you to participate in this annual meeting, which is important for the future of the Company.

As you most likely read in our last [Shareholders Letter of May 04 \(N°14\)](#), **2023 could be, for GENFIT, a year with a new dynamic for the following reasons:**

- Financially, **our cash position at the end of 2022 is healthy**, with €140 million cash and cash equivalents expected to fund all of our current programs through the third quarter of 2024;
- **Topline data for our pivotal study in Primary Biliary Cholangitis (PBC) ELATIVE® are expected at the end of the second quarter** (in approximately two months);
- **Four key milestones are expected for GENFIT's other drug candidates by the end of 2023:**
  - > **Acute-on-chronic-liver failure (ACLF):**
    - ◇ Second quarter:
      - » a first patient is expected to be screened for the Phase 2 study evaluating VS-01-ACLF
      - » we will announce the conclusions from the results of the two Phase 1 studies evaluating NTZ
    - ◇ Second half of the year:
      - » potential launch of a Phase 2a study on NTZ
  - > **Cholangiocarcinoma (CCA):**
    - ◇ Towards the end of the second quarter:
      - » a first patient is expected to be screened for the Phase 1b/2a study evaluating GNS561

**Your participation in the Combined Shareholders Meeting of May 24 will enable the Company to renew the authorizations necessary to pursue this new dynamic for the future.** I invite you, therefore, to carefully review the resolutions proposed by the Board of Directors and the instructions to vote by post or online via the electronic platform, if you are unable to be present in person.

**We are counting on your vote,**

Pascal Prigent

...

# Procedure to vote

## 1. Why should you vote?

As a GENFIT shareholder, **you can support the Company by voting at the Combined Shareholders Meeting** and by giving the Board of Directors the means to execute its development strategy. It is thanks to your support in our past shareholders meetings that we were able to best add value to the PBC program with Ipsen in

2021, and prepare the future with the Versantis acquisition in 2022.

**Your vote is therefore precious**, and we count on your vote at the next Combined Shareholders Meeting on May 24, 2023.

## 2. How to vote?

As with every year, we have the pleasure to host the Combined Shareholders Meeting at the Lille Faculty of Pharmacy at 10.00am CET on first convening.

**If you are unable to be physically present**, it is possible to vote remotely by post or online **via the online voting platform Votaccess\*** (a secured website) opened from May 05 **until May 23 at 3.00pm** (French time).

You can also vote on the resolutions sent **by post before the meeting** either by:

- ➔ Voting via mail-in voting form;
- ➔ Designating a representative before the

Combined Shareholders Meeting; or

➔ Giving proxy to the Chairman of the Shareholders Meeting.

To do so, you can check our **convening notice** available on our [website](#) and follow the instructions as soon as possible so that your registration can be taken into account

In the event that a quorum is not met for the Shareholders Meeting, a new Meeting will be reconvened with the same agenda on June 07, 2023, at 10am CET in the Company's head office.

\*If your broker has signed up to the platform

More information on the May 24 Combined Shareholders Meeting, how to participate and a tutorial on using the online voting platform Votaccess can be found on the Company's website

A toll-free phone number is also available to answer all questions relating to the voting procedures:

- 0 805 321 079 (France only); or
- +33 (0)1 78 90 69 14 (if calling from abroad) from Monday to Friday from 10.00pm to 7.00pm CET

GENFIT | [investors@genfit.com](mailto:investors@genfit.com) | <https://ir.genfit.com/fr/>

This Shareholders' Letter contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995 in relation to timelines for topline data readout for our ELATIVE® Phase 3 trial, potential for positive ELATIVE® Phase 3 results, eligibility to meet milestones and receive payments from Ipsen, timelines for data readout in NTZ in ACLF Phase 1 trials, timelines for patient screening and enrollment in our VS-01 ACLF and GNS561 in CCA programs, timelines for the initiation of a Phase 2a proof of concept study evaluating NTZ in patients with ACLF grades 1 and 2, commercial perspectives for elafibranor in PBC and its potential as a therapeutic option for patients, potential market sizes in the disease areas where we develop our product candidates, our ability to qualify for and obtain specific regulatory pathways, our financial outlook including cash flow and cash burn projections and business activity projections for 2023 and beyond. The use of certain words, including "consider", "contemplate", "think", "aim", "expect", "understand", "should", "aspire", "estimate", "targeted", "anticipated", "believe", "wish", "may", "could", "allow", "seek", "encourage" or "have confidence" or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, cost of, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, exchange rate fluctuations, potential synergies related to the acquisition of Versantis, our capacity to integrate its assets, develop its programs and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Main Risks and Uncertainties" of the Company's 2022 Universal Registration Document filed with the AMF on April 18, 2023 under n° D.23-0304, which is available on the Company's website ([www.genfit.com](http://www.genfit.com)) and on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)) and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC") including the Company's 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023. In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.